Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Breast cancer subtype biomarker distinguishing composition

A technology for biomarkers and breast cancer, applied in material separation, analysis materials, measurement devices, etc., can solve problems such as distinguishing molecular types of breast cancer

Active Publication Date: 2015-10-21
CHINA PHARM UNIV
View PDF7 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

No one has used plasma metabolite levels to differentiate breast cancer molecular subtypes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Breast cancer subtype biomarker distinguishing composition
  • Breast cancer subtype biomarker distinguishing composition
  • Breast cancer subtype biomarker distinguishing composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0077] The composition and relative peak intensities of biomarker combinations used to distinguish Luminal B type breast cancer from HER2 overexpression type are shown in Table 2:

[0078] Table 2 Differential metabolites of Luminal B type vs HER2 overexpression breast cancer

[0079]

[0080] a VIP variable importance projection; b EIC extracts ion current; c HER2 overexpression type relative to Luminal B type breast cancer differential metabolite extraction ion current peak intensity change trend.

Embodiment 2

[0082] The composition and relative peak intensities of the biomarker combinations used to distinguish between Luminal A and Basal-like breast cancers are shown in Table 3:

[0083] Table 3 Differential metabolites of Luminal A type vs Basal-like breast cancer

[0084]

[0085] a VIP variable importance projection; b EIC extracts ion current; c The change trend of ion current peak intensity of differential metabolite extraction between Basal-like type and Luminal A type breast cancer.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a biomarker for distinguishing Lumina1 B vs HER2 overexpression breast cancers and Luminal A vs Basal-like breast cancers based on patient blood plasma metabonomics researches of different molecule subtypes of breast cancers. Compared with HER2 overexpression breast cancer patient's blood plasma, the Lumina1 B breast cancer patient's blood plasma has obviously up-regulated proline, isoleucine, leucine, 2-octendioic acid and valine and obviously down-regulated piperidinecarboxylic acid; and compared with Basal-like breast cancer patient's blood plasma, the Lumina1 A breast cancer patient's blood plasma has obviously up-regulated valine and obviously down-regulated piperidinecarboxylic acid, glycine, glycochenodeoxycholic acid and palmitic acid. The biomarker can rapidly predicate breast cancer molecule subtypes, and provides important bases for clinic diagnosis, treatment and prognosis evaluation of the breast cancers.

Description

technical field [0001] The present invention relates to the field of tumor biomarkers, in particular to a composition of biomarkers of a group of molecular subtypes of breast cancer. The composition is derived from plasma endogenous small molecule metabolites. Subtype and clinical individualization of treatment are of great importance. Background technique [0002] Breast cancer is the most common malignant tumor in women, with strong heterogeneity, and its morbidity and mortality have been gradually increasing in recent years. Human epidermal growth factor receptor 2 (HER2) is a proto-oncogene in breast cancer patients. Its high level of expression indicates that patients are prone to axillary lymph node metastasis. It is clinically recommended to use corresponding molecular targeted drugs for intervention. The expression of estrogen receptor (ER) is an indispensable and important basis for the application of endocrine drug therapy. According to the gene expression of HER...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N30/02
Inventor 齐炼文李进朱伟范勇
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com